Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings

Core Insights - Neurocrine Biosciences reported $687.5 million in revenue for Q2 2025, a 16.5% year-over-year increase, with an EPS of $1.06 compared to $0.63 a year ago, exceeding both revenue and EPS consensus estimates [1][4] Revenue Breakdown - Product sales, net reached $682 million, surpassing the estimated $635.87 million, reflecting a 16.8% increase year-over-year [4] - Collaboration revenue was reported at $5.5 million, below the estimated $6.04 million, marking a 14.1% decline year-over-year [4] - Product sales for INGREZZA were $624.4 million, slightly above the $620.8 million estimate, with a year-over-year growth of 7.8% [4] - CRENESSITY product sales were reported at $53.2 million, significantly exceeding the $19.82 million estimate [4] - Other product sales amounted to $4.4 million, slightly above the $4 million estimate [4] - Royalty collaboration revenue was $5.1 million, slightly below the $5.35 million estimate [4] Stock Performance - Neurocrine's shares have returned +4.8% over the past month, outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]